THE Australian Influenza Vaccine Committee (AIVC) met at the offices of the Therapeutic Goods Administration (TGA), Canberra, on 09 Oct, and has now handed down its recommendations for influenza viruses to be used in the composition of the influenza vaccines for 2020.
Quadrivalent vaccines are to include an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A/South Australia/34/2019 (H3N2)-like virus, a B/Washington/02/2019-like (B/Victoria lineage) virus and a B/Phuket/3073/2013-like (B/Yamagata lineage) virus.
Trivalent vaccines are to contain an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A/South Australia/34/2019 (H3N2)-like virus and a B/Washington/02/2019-like (B/Victoria lineage) virus.
See full details around the recommendations at tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Oct 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Oct 19
